FGF21, fibroblast growth factor 21, 26291

N. diseases: 236; N. variants: 2
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0028754
Disease: Obesity
Obesity 		0.400 Biomarker disease BEFREE FGF-21-transgenic mice were viable and resistant to diet-induced obesity. 15902306 2005
CUI: C0011847
Disease: Diabetes
Diabetes 		0.100 Biomarker disease BEFREE Thus, we conclude that FGF-21, which we have identified as a novel metabolic factor, exhibits the therapeutic characteristics necessary for an effective treatment of diabetes. 15902306 2005
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus 		0.100 Biomarker group BEFREE Thus, we conclude that FGF-21, which we have identified as a novel metabolic factor, exhibits the therapeutic characteristics necessary for an effective treatment of diabetes. 15902306 2005
CUI: C0011860
Disease: Diabetes Mellitus, Non-Insulin-Dependent
Diabetes Mellitus, Non-Insulin-Dependent 		0.400 Biomarker disease LHGDN The present work suggests a potential role for FGF-21 in the pathogenesis of insulin resistance and T2DM. 17926232 2008
CUI: C0028754
Disease: Obesity
Obesity 		0.400 AlteredExpression disease BEFREE Serum FGF21 levels in overweight/obese subjects were significantly higher than in lean individuals. 18252893 2008
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X 		0.100 Biomarker disease BEFREE Furthermore, the increased risk of the metabolic syndrome associated with high serum FGF21 was over and above the effects of individual components of the metabolic syndrome. 18252893 2008
CUI: C0011860
Disease: Diabetes Mellitus, Non-Insulin-Dependent
Diabetes Mellitus, Non-Insulin-Dependent 		0.400 Biomarker disease BEFREE Fibroblast growth factor 21 (FGF21) is active in murine adipocytes and has beneficial metabolic effects in animal models of type 2 diabetes mellitus. 18460341 2008
CUI: C0003125
Disease: Anorexia Nervosa
Anorexia Nervosa 		0.020 Biomarker disease LHGDN Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa. 18559909 2008
CUI: C0011860
Disease: Diabetes Mellitus, Non-Insulin-Dependent
Diabetes Mellitus, Non-Insulin-Dependent 		0.400 AlteredExpression disease BEFREE Moreover, very recent results from different human cohort studies have shown a paradoxical regulation of plasma FGF21 in obesity and type 2 diabetes as well as other important qualitative differences in the effects and regulation of FGF21 between rodents and humans. 19277467 2009
CUI: C0028754
Disease: Obesity
Obesity 		0.400 AlteredExpression disease BEFREE Moreover, very recent results from different human cohort studies have shown a paradoxical regulation of plasma FGF21 in obesity and type 2 diabetes as well as other important qualitative differences in the effects and regulation of FGF21 between rodents and humans. 19277467 2009
CUI: C0020456
Disease: Hyperglycemia
Hyperglycemia 		0.100 Biomarker disease BEFREE A large amount of data, predominantly obtained from murine models but also from non-human primates, suggest that FGF21 ameliorates obesity-associated hyperglycemia and hyperlipidemia primarily via effects on adipose tissue and the pancreas. 19277467 2009
CUI: C0022638
Disease: Ketosis
Ketosis 		0.050 Biomarker disease BEFREE In addition, FGF21 has been reported to play a pivotal regulatory role in starvation and ketosis. 19277467 2009
CUI: C0020473
Disease: Hyperlipidemia
Hyperlipidemia 		0.030 Biomarker disease BEFREE A large amount of data, predominantly obtained from murine models but also from non-human primates, suggest that FGF21 ameliorates obesity-associated hyperglycemia and hyperlipidemia primarily via effects on adipose tissue and the pancreas. 19277467 2009
CUI: C0011860
Disease: Diabetes Mellitus, Non-Insulin-Dependent
Diabetes Mellitus, Non-Insulin-Dependent 		0.400 Biomarker disease BEFREE The results presented here offer a mechanism explaining the induction of the metabolic regulator FGF-21 in the fasting situation but also in type 2 diabetes and obesity. 19401423 2009
CUI: C0028754
Disease: Obesity
Obesity 		0.400 Biomarker disease BEFREE The results presented here offer a mechanism explaining the induction of the metabolic regulator FGF-21 in the fasting situation but also in type 2 diabetes and obesity. 19401423 2009
CUI: C0020459
Disease: Hyperinsulinism
Hyperinsulinism 		0.070 AlteredExpression disease BEFREE An artificial hyperinsulinemia, which was induced to delineate the potential interaction between elevated FFAs and hyperinsulinemia, revealed that hyperinsulinemia also increased FGF-21 levels in vivo, while rosiglitazone treatment had no effect. 19401423 2009
CUI: C0011860
Disease: Diabetes Mellitus, Non-Insulin-Dependent
Diabetes Mellitus, Non-Insulin-Dependent 		0.400 AlteredExpression disease BEFREE FGF21 levels in obesity did not significantly differ from T2DM group. 19702724 2009
CUI: C0028754
Disease: Obesity
Obesity 		0.400 AlteredExpression disease BEFREE VLCD significantly increased FGF21 mRNA expression in subcutaneous fat of obesity. 19702724 2009
CUI: C0020459
Disease: Hyperinsulinism
Hyperinsulinism 		0.070 AlteredExpression disease BEFREE 3-h hyperinsulinaemia during the clamp increased FGF21 levels in T2DM but not in C group. 19702724 2009
CUI: C0022638
Disease: Ketosis
Ketosis 		0.050 Biomarker disease BEFREE Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. 19819944 2009
CUI: C0025517
Disease: Metabolic Diseases
Metabolic Diseases 		0.100 Biomarker group BEFREE Fibroblast growth factor 21 (FGF21) is a promising drug candidate to combat metabolic diseases. 20163718 2010
CUI: C0028754
Disease: Obesity
Obesity 		0.400 Biomarker disease BEFREE Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. 20451522 2010
CUI: C0400966
Disease: Non-alcoholic Fatty Liver Disease
Non-alcoholic Fatty Liver Disease 		0.400 AlteredExpression disease BEFREE Serum FGF21 and hepatic mRNA expression were measured in obese individuals with NAFLD or NASH. 20451522 2010
CUI: C3241937
Disease: Nonalcoholic Steatohepatitis
Nonalcoholic Steatohepatitis 		0.330 AlteredExpression disease BEFREE We also evaluated FGF21 serum levels and liver messenger RNA (mRNA) expression in nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). 20451522 2010
CUI: C4529962
Disease: Fatty Liver Disease
Fatty Liver Disease 		0.070 AlteredExpression disease BEFREE Serum FGF21 and hepatic mRNA expression were measured in obese individuals with NAFLD or NASH. 20451522 2010